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Abstract: Posaconazole is the newest azole antifungal approved by the US Food and Drug 
Administration, and possesses a broad spectrum of activity against numerous yeasts and 
  filamentous fungi. It is available as an oral suspension and is generally well tolerated by patients, 
but gastrointestinal absorption is sometimes inadequate and remains a clinical concern in treat-
ing deep-seated infections. It is used routinely and effectively for the prophylaxis of invasive 
fungal infections in immunosuppressed hosts and is an effective treatment of oropharyngeal 
candidiasis, including azole-resistant disease.
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Overview of oropharyngeal candidiasis
The frequency of Candida species infections in humans continues to increase. There 
are many manifestations of the disease, some trivial and some life-threatening. The 
most common candidal infection is mucocutaneous oropharyngeal candidiasis (OPC). 
Thrush is the classic lesion of OPC and is recognized by the presence of creamy white, 
curd-like patches on the soft and hard palate and other oral mucosal surfaces. Diagnosis 
is confirmed by scraping one of the lesions and using potassium   hydroxide or Gram 
stain of scraped material which on microscopy demonstrates hyphae, pseudohyphae, 
and/or yeast forms with scattered polymorphonuclear leukocytes. The fungi are usually 
entangled with Gram positive cocci.1 Other manifestations of OPC include atrophy 
of the tongue or acute atrophic candidiasis, “denture sore mouth” or chronic atrophic 
candidiasis (inflammation under the dental plates), angular cheilitis (inflammation at 
the corners of the mouth), and Candida leukoplakia (firm, white patches, persistently 
present on the oral mucosa).2
The Candida species commonly associated with OPC is C. albicans.2 In human 
immunodeficiency virus (HIV)-positive individuals, C. albicans is isolated in over 
70% of the patients, and less often C. glabrata, C. tropicalis, C. parapsilosis,3 
or C. dublinensis are found.4 OPC is common in HIV-positive patients with CD4 
counts lower than 200 cells/µL, immunocompromised patients on chemotherapy, 
patients on systemic steroids, or patients who use inhaled steroids. Approximately 
80%–90% of patients with acquired immunodeficiency syndrome (AIDS) will 
develop OPC.5
Preferred therapy for OPC differs by patient population. For example, therapy in the 
HIV patient may differ from that in a patient with immunosuppression secondary to ste-
roids or chemotherapy. In HIV-negative patients with mild OPC, treatment consists of Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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local antifungal lozenges or solutions, eg,   nystatin swish and 
swallow four times a day or clotrimazole troches (one 10 mg 
troche five times daily). If local therapy does not work, oral 
therapy is recommended, such as   fluconazole 200 mg once 
daily, then 100–200 mg daily.6 These   recommendations 
are derived from a consensus of authorities, with moderate 
  evidence for or against the use of a regimen based upon 
more than one well-designed clinical study.6   Recurrence 
is   common if underlying risk factors are still present 
(eg, continued use of steroids or chemotherapy). In HIV-
positive patients with OPC, treatment also varies depending 
on the severity of disease. Topical agents can be used in mild 
OPC, but oral azoles are indicated in moderate to severe 
OPC. Antiretroviral drugs are essential in the treatment and 
eradication of OPC in AIDS patients; if antiretrovirals are 
not started, the rate of relapse is high. Topical treatment has 
no role if esophageal candidiasis is present.6
Microbiological aspects  
of posaconazole
Posaconazole is a triazole antifungal agent that has struc-
tural similarities to itraconazole. Posaconazole inhibits 
the synthesis of ergosterol (a sterol component of fungal 
cell membranes) by inhibition of the enzyme, lanosterol 
14-  alpha demethylase, with accumulation of methylated 
sterol precursors.7 In contrast with other azole   antifungals, 
posaconazole is not extensively metabolized by the CYP450 
enzymes.8 In vitro tests have shown   posaconazole to be active 
against Candida species, Aspergillus species,   Coccidioides 
species, Fusarium species, Histoplasma   capsulatum, 
  Zygomycetes, Phaeohyphomycetes, and other filamen-
tous fungi. In addition, posaconazole has demonstrated 
activity against fluconazole- and itraconazole-resistant 
Candida species, as well as itraconazole-, voriconazole-, 
and amphotericin B-resistant Aspergillus fumigatus, and 
activity against Cryptococcus neoformans.9 Posaconazole 
is fungistatic against some   Candida species (C. albicans, 
C. glabrata, C.     parapsilosis, and C. tropicalis), but is 
fungicidal against other Candida species (C. lusitaniae, 
C. krusei, C. kefyr, and C. inconspicua).10 Clinical uses 
of posaconazole that are Food and Drug Administration 
(FDA)-approved include prophylaxis of invasive aspergil-
losis in high-risk patients, prophylaxis of disseminated 
candidiasis in severely immunocompromised patients, 
and treatment of OPC, including the treatment of OPC 
refractory to itraconazole and/or fluconazole. Clinical 
applications that are not FDA-approved include invasive 
aspergillosis or esophageal candidiasis.
OPC treatment and a comparator 
drug, fluconazole
Fluconazole is a triazole with greater than 90% bioavailability 
after oral administration and has been extensively used for 
treatment of a wide range of Candida infections, in particular, 
OPC.6 Although OPC usually responds to fluconazole, if 
underlying predisposing factors are not corrected, OPC can 
recur. There have been a number of reports of fluconazole 
failure or resistance in AIDS patients.11 However, it is dif-
ficult to establish a definition of resistance. In some cases, 
the term is used when a patient fails to respond clinically to 
antifungal therapy, and in other cases, resistance is described 
by the minimum inhibitory concentration (MIC) of the drug. 
While correlations between the fluconazole MIC and out-
come have been established in animal models, therapeutic 
failures and successes in humans may be seen with isolates 
for which MICs are both high and low.12 MIC breakpoints for 
fluconazole remain unclear, but the Clinical and Laboratory 
Standards Institute methodology recommends the follow-
ing breakpoints: susceptible (S) MIC # 8 µL; susceptible, 
dose-dependent (SDD) MIC 16–32 µL that predicts a poor 
response to 100 mg a day of fluconazole orally; or resistant 
(R) MIC . 64 µL.13 On the basis of previously published 
data, it appears that resistance occurs in roughly 5% of 
patients with advanced AIDS.3 The largest group of failures 
reported outside of patients with AIDS and OPC consists of 
patients with fungemia. In both groups, one of the major fac-
tors predicting fluconazole resistance is low-dose fluconazole 
used as prophylaxis.12 
The clinical significance of fluconazole resistance as 
defined in the laboratory is not fully known. Most OPC 
cases described in the literature of fluconazole resistance 
have been in AIDS patients. The clinical significance of 
fluconazole resistance was assessed in 50 HIV-positive 
patients with recurrent OPC in a study by Revankar et al.14 
Resistant yeast was defined as an MIC . 8 µL. Thirty-two 
of 50 patients were found to have resistant Candida (11 had 
MIC . 32 µL), but almost all patients responded clinically to 
fluconazole (48/50), which suggests that the clinical efficacy 
of fluconazole remains high.14
Resistance issues: azole-resistant 
Candida species
Several mechanisms give rise to resistance to azole drugs. 
One is mutation in the gene, ERG11, which encodes the target 
enzyme of azoles, ie, lanosterol demethylase. Another resis-
tant mechanism of Candida species is overexpression of drug Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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efflux pumps. Posaconazole, however, is not a substrate for 
two major pumps, MDR1 and FLU1, that confer resistance 
to voriconazole or fluconazole.15 In fact, posaconazole may 
have clinical activity against fluconazole-resistant Candida 
species.11 Posaconazole has good activity against Candida 
species that are less susceptible to fluconazole (eg, C.   krusei, 
C. guilliermondii, and C. dublinensis), but is less active 
against C. glabrata.9 Based on MIC90 values, posaconazole 
was found to be more potent than fluconazole and equal or 
more potent than itraconazole, voriconazole, and ampho-
tericin B against these isolates.9 However, more than half 
of Candida isolates resistant to fluconazole were also less 
susceptible to posaconazole.16 The clinical significance of 
these findings is unknown.10
Pharmacology and 
pharmacokinetics of posaconazole
Guidelines developed by the Infectious Diseases Society 
of America for candidiasis recommend posaconazole for 
fluconazole-refractory OPC at a dose of 400 mg orally twice 
daily for three days, followed by 400 mg orally once daily 
for up to 28 days.6 However, the manufacturer’s dosing 
information is slightly different. For treatment of OPC, the 
loading dose is 100 mg (2.5 mL) orally twice daily for one 
day, then 100 mg orally once daily for 13 days. The manu-
facturer’s recommendation for treatment of OPC refractory 
to itraconazole and fluconazole is 400 mg (10 mL) twice a 
day for a duration based on the severity of the disease and 
clinical response.17
Posaconazole is given orally. The oral solution is admin-
istered during or within 20 minutes of a full meal or a   liquid 
nutritional supplement. Alternatively, the drug can be admin-
istered with an acidic carbonated drink. It should be stored at 
25°C. There is no dose adjustment recommended for renal or 
liver failure.8,18 The structural formula is shown in Figure 1.
Following multiple dose administration, steady-state 
plasma concentrations are attained at 7–10 days. During twice 
daily dosing of posaconazole over 14 days, mean peak plasma 
concentrations were achieved on day 1 at five hours and eight 
hours following the administration of the first and second 
dose, respectively. On day 14, peak plasma concentrations 
were observed at 4–6 hours and at 9–11 hours following the 
administration of the first and second doses, respectively.19 
Absorption is influenced by the frequency of doses and 
meals. Posaconazole is absorbed better if taken with meals, 
especially high-fat meals. Acidic carbonated beverages also 
increase absorption.20
Posaconazole is 98% protein-bound, mostly to albumin. 
It is lipophilic and has a high volume of distribution sug-
gesting extensive extravascular distribution and penetration 
into body fluids, bone, central nervous system, eye, and 
pulmonary epithelial lining fluid. A very small percentage 
of posaconazole is metabolized and the majority of the drug 
is eliminated from the body unchanged. Less than 30% is 
metabolized by the liver through glucuronidation and is trans-
formed into biologically inactive metabolites.21 The majority 
of posaconazole is excreted in the feces up to 120 hours after 
a dose. Only 13%–14% of posaconazole is excreted in the 
urine.18 Mean total body clearance is 32 L/hour. The elimi-
nation half-life of the parent compound is 35 hours, with a 
range of 20–66 hours.20
Efficacy studies in OPC
The clinical efficacy of posaconazole in OPC was investigated 
in two major studies done in HIV-positive patients. In a mul-
ticenter, randomized, evaluator-blinded trial by Vasquez et al 
in 2006, posaconazole was compared with fluconazole in the 
treatment of OPC in HIV-infected patients.22 The   primary end-
point was clinical success (cure or improvement) on day 14. 
This was evaluated in 329 patients. Other secondary endpoints 
were mycologic success, defined as a quantitative yeast cul-
ture yielding  20 colony forming units (cfu)/mL of   Candida 
species and eradication, defined as 0 cfu/mL. Persistence 
(nonsuccess) was defined as .20 cfu/mL of Candida species. 
Relapse was defined as  20 cfu/mL of Candida species on day 
14 and  20 cfu/mL on day 42. Durability of clinical success 
was evaluated on day 42. Posaconazole was administered to 
178 patients and 172 received fluconazole. Clinical success 
occurred in 91.7% of posaconazole recipients and in 92.5% 
of fluconazole recipients, indicating that posaconazole was 
not inferior to fluconazole. On day 14, mycologic success 
was 68% in both arms, but by day 42, significantly more 
posaconazole recipients than fluconazole continued to have 
mycological success (40.6% versus 26.4%, respectively). 
Fewer posaconazole recipients than fluconazole experienced 
clinical relapse (31.5% versus 38.2%). Adverse effects were 
similar between the treatment arms.22
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The efficacy and safety of oral posaconazole was 
  evaluated in a Phase III, open-label study by Skiest et al in 
2007.11 The study consisted of 176 HIV-infected patients 
with confirmed esophageal candidiasis or OPC who 
failed previous fluconazole or itraconazole therapy or had 
  laboratory-confirmed resistant mucosal candidiasis. Posa-
conazole was administered to 103 subjects at 400 mg twice 
daily for three days, followed by posaconazole 400 mg once 
daily for 25 days, and 96 patients received posaconazole 400 
mg twice daily for 28 days. There was a clinical response 
(cure or improvement) in 75.3% of patients after receiv-
ing 28 days of posaconazole treatment. Clinical response 
rates were similar between both arms of the study. Clinical 
responses were also similar in different patients with base-
line isolates resistant to fluconazole, itraconazole, or both. 
The most common treatment-related adverse events were 
diarrhea (11%), neutropenia (7%), flatulence (6%), and 
nausea (6%). Table 1 summarizes the clinical studies with 
posaconazole in HIV patients.
Few studies have looked at posaconazole as prophy-
laxis in neutropenic patients. Posaconazole is approved for 
prophylaxis of emergent filamentous fungi in patients with 
neutropenia from acute myelogenous leukemia or myelodys-
plastic syndrome. In a multicenter study published in 2007 by 
Cornely et al, posaconazole was compared with fluconazole 
or itraconazole as prophylaxis for invasive fungal infections 
in patients with prolonged neutropenia.23 Three hundred and 
four patients were randomly assigned to receive posacon-
azole 200 mg three times daily and 298 patients received 
fluconazole 400 mg daily or itraconazole 200 mg twice 
daily. Proven or probable invasive fungal infections were 
reported in seven patients (2%) in the posaconazole group 
and 25 patients (8%) in the fluconazole or itraconazole group. 
The majority of fungal infections were caused by Aspergillus 
species and there was a clear superiority of posaconazole over 
fluconazole. Invasive candidiasis occurred in three patients 
who received posaconazole, in two patients in the fluconazole 
arm, in none in the itraconazole arm, and the results were 
not statistically significant. This study showed posaconazole 
to be more effective in preventing invasive fungal diseases 
and improving survival. 
Another international study by Ullmann et al in 2007 
looked at prophylaxis against invasive fungal infections in 
patients with graft-versus-host disease (GVHD) on immu-
nosuppressive treatment and compared posaconazole with 
fluconazole.24 This was a randomized, double-blind trial 
including patients who received an allogeneic hematopoietic 
stem cell transplant and developed GVHD. Posaconazole 
200 mg three times daily was administered to 301 patients, 
and 299 patients received fluconazole 400 mg once daily. 
Posaconazole was found to be as effective as fluconazole in 
preventing all invasive   fungal infections, but was superior 
to fluconazole in preventing proven or probable invasive 
aspergillosis and reducing the rate of deaths related to 
fungal infections. Colonization with   Candida species was 
assessed and the development of resistance was found to 
be higher among patients taking fluconazole (17%) than 
posaconazole (5%).
There have been numerous studies in vitro and in mice 
showing the potency of posaconazole against different 
fungi. Pfaller et al compared the new triazole derivatives, 
ie, posaconazole, ravuconazole, and voriconazole with itra-
conazole and amphotericin B against 239 clinical isolates of 
filamentous fungi. All the new azoles had excellent activity 
against Aspergillus species, posaconazole was better than 
voriconazole for Rhizopus, and none of them had activity 
against Fusarium or Mucor,25 although other studies showed 
in vivo activity against a few Fusarium species.26
Another study by Sabatelli et al compared the activity 
of posaconazole with itraconazole, fluconazole, voricon-
azole, and amphotericin B against 19,000 strains of yeasts 
and molds.9 Posaconazole was more active than, or within 
1 dilution of, the comparator drugs against 7000 isolates 
of Candida and Cryptococcus species. Also, posaconazole 
was active against species of Candida and Aspergillus 
which showed resistance to fluconazole, voriconazole, 
Table 1 evidence for use of posaconazole in HIv patients with OPC and/or esophageal candidiasis
Study Study design Study population Posaconazole Fluconazole Results
Skiest et al11 Phase III,  
open-label
OPC or eC with  
refractory disease  
to fluconazole,  
199 patients
400 mg bid for 3 days,  
then 400 mg qd for 25 days  
or 400 mg bid  
for 28 days
75% clinical  
response
vasquez et al22 Randomized,  
evaluator-blinded
OPC, 350 patients 200 mg first day, then 
100 mg qd for 13 days
200 mg first day, then  
100 mg qd for 13 days
Posaconazole as  
effective as  
fluconazole, CI 95%
Abbreviations: EC, esophageal candidiasis; OPC, oropharyngeal candidiasis; qd, once daily, CI, confidence interval.Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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and   amphotericin B, and was much more active than other 
  triazoles against Zygomycetes.
Posaconazole efficacy was studied in mice against 
C. glabrata isolates with various susceptibilities to flucon-
azole by Spreghini et al in 2008.27 Posaconazole was found 
to be significantly effective against all the strains.
Posaconazole safety and tolerability
In a study by Vazquez et al, 64% of posaconazole therapy 
recipients (114/178) and 68% of fluconazole therapy recipi-
ents (117/172) reported adverse events during 14 days of 
OPC treatment.22 In the posaconazole and fluconazole 
treatment groups, only 25% and 24% of these events were 
determined to be posaconazole-related, respectively. The 
most commonly reported adverse events were diarrhea 
(15% posaconazole and 20% fluconazole groups) and 
nausea (17% posaconazole and 15% fluconazole groups). 
Other reported adverse events (.5%) in the posaconazole 
treatment group included headache (13%), vomiting (11%), 
fever (10%), abdominal pain (8%), and dizziness (6%), that 
were similar to rates reported in the fluconazole treatment 
arm. Other serious reported adverse events in the posacon-
azole arm included asthenia, respiratory insufficiency, and 
lymphadenopathy, but none of these events were associated 
with posaconazole therapy.22
In a study by Skiest et al, adverse events were reported 
in 49% of the 199 subjects in the intent-to-treat posacon-
azole OPC 28-day treatment arms.11 Commonly reported 
adverse events included nausea (12%), diarrhea (21%), 
flatulence (11%), abdominal pain (10%), headache (9%), 
vomiting (9%), dizziness (7%), fatigue (6%), and rash 
(6%).   Neutropenia (n = 28) was the most common reported 
adverse event during posaconazole therapy but only 7% were 
possibly or probably associated with posaconazole therapy. 
QTc prolongation, epistaxis, rash, edema, hypersensitivity, 
vomiting, or laboratory abnormalities led to discontinuation 
of posaconazole therapy in 11 subjects.11 Overall, many 
of these adverse events are common in HIV-infected or 
immunocompromised patients due to the disease state and 
other therapies utilized, including antiretroviral agents and 
chemotherapy.
While generally well tolerated, patients receiving posa-
conazole therapy for OPC should be monitored for liver 
and cardiac dysfunction. Posaconazole should be used with 
caution in patients with a history or development of adrenal 
insufficiency, liver dysfunction or failure, and QT interval 
prolongation.17 During posaconazole therapy for OPC, liver 
function tests including bilirubin levels may rise due to 
cholestasis. Liver enzymes should be periodically monitored. 
Serum electrolyte levels, specifically potassium, magnesium, 
and calcium, should be monitored due to risk of hypocalcemia 
(9%), hypokalemia (3%), and hypomagnesemia (18%)   during 
posaconazole therapy. As with any medication, patients 
should be screened prior to use for previous intolerance or 
contraindications to posaconazole or similar triazole-class 
agents.17
Administration of posaconazole with a cytochrome P450 
3A4 substrate should be evaluated prior to start of therapy. 
Posaconazole has no significant effect on CYP enzymes 
except CYP3A4. In a study done by Wexler et al,8 posa-
conazole inhibits CYP3A4 at submicromolar concentra-
tions, and other enzymes were not inhibited ( CYP1A2, 
2A6, 2C9, 2C19, and 2D6). All azoles inhibit CYP3A4, 
but the other azoles inhibit some of the other enzymes 
too, eg,   fluconazole and itraconazole inhibit 1A2 and 2C, 
whereas voriconazole inhibits 2C9 and 2C19. This means 
fewer drug inhibitions by posaconazole overall. Contrain-
dications to taking posaconazole are the concurrent use 
of sirolimus, ergot   alkaloids, and the CYP3A4 substrates 
terbenafine, astemizole, cisapride, pimozine, halofantrine, 
and quinidine.   Caution should be exercised in patients with 
  hypersensitivity to other azoles and potentially proarrhyth-
mic conditions. Serious side effects reported include adrenal 
insufficiency, cholestasis, hyperbilirubinemia, increased 
liver enzymes, liver damage, liver failure, and prolonged 
QT interval.17 One study found that adverse effects were not 
dose-dependent.19 Depending on the degree of interaction, 
alternative therapy or dosage adjustments may be necessary 
during posaconazole therapy. Additionally, the coadminis-
tration of posaconazole and agents with known increased 
risk of QT prolongation or liver dysfunction should be 
used with caution. Due to risk of ergotism, administration 
of ergot alkaloids with posaconazole is contraindicated. 
Coadministration of posaconazole with acid-blocking 
agents should be evaluated due to their potential to decrease 
absorption of posaconazole and therefore decrease serum 
posaconazole levels during OPC treatment.
Patient satisfaction, acceptability, 
adherence, and uptake
Outpatient and inpatient compliance along with patient sat-
isfaction and quality of life with posaconazole OPC therapy 
is dependent on a variety of factors, including incidence of 
adverse events, efficacy, dosage frequency, and drug cost. 
Many of these factors are similar for posaconazole and 
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As reported by Skiest et al and Vazquez et al rates of 
  common adverse events such as nausea, vomiting, and 
diarrhea are similar between fluconazole and posaconazole 
for OPC therapy.11,22 In the study by Vazquez et al, 88% 
and 89% of enrolled patients with OPC completed the 
treatment phase of posaconazole and fluconazole therapy, 
respectively, as prescribed. Reasons determined for early 
discontinuation of therapies included adverse events (4% 
for both treatment groups), treatment failures (2% for both 
treatment groups), and noncompliance or loss to follow-up, 
including death (6% posaconazole group and 5% fluconazole 
group).22 In the study by Skiest et al, therapy was completed 
in 75% of the 199 HIV-infected subjects in an intent-to-treat 
posaconazole OPC 28-day treatment regimen. Reasons for 
discontinuation of treatment were adverse events (23%), 
treatment failure (5%), non-compliance (12%), death (4%), 
and other (3%).11
Based on currently published reports, duration of therapy 
and dosing schedule is similar for both posaconazole and 
fluconazole for OPC treatment. Posaconazole OPC treat-
ment regimens generally involve either daily or twice daily 
dosing. This dosing frequency is significantly less compared 
with standard posaconazole therapy recommended at three 
to four times daily for more serious systemic infections. 
Patient education should include an evaluation of a patient’s 
dietary intake, including timing of dose with meals. Since it 
is recommended that posaconazole therapy be administered 
with food, posaconazole frequency may be adjusted in certain 
patients to maximize compliance of therapy with food intake. 
While posaconazole therapy has been shown to be effica-
cious in treatment of OPC, posaconazole therapy may not be 
feasible, and alternative therapy may need to be evaluated if 
a patient has difficulty with oral medication absorption due 
to factors such as significant nausea and vomiting, limited 
oral intake or use of acid-blocking agents, or gastrointestinal 
tract dysfunction, including ileus and mucositis.
Whether therapy is prescribed for outpatient or inpatient 
use, the patient’s financial and insurance status may be a 
barrier to posaconazole therapy. A generic formulation of 
posaconazole is not currently available in the US, unlike 
other triazole agents such as fluconazole and itraconazole. 
Certain insurance companies or institutions may require prior 
authorization based on formulary restrictions. Additionally, 
the immediate availability of posaconazole suspension at cer-
tain medical centers, clinics, and community pharmacies may 
be limited and dependent on regional patient populations. 
Overall, to increase patient compliance with OPC posacon-
azole therapy, patients should receive information related to 
the purpose of treatment, directions for administration, and 
potential side effects of posaconazole therapy.
Conclusions
Posaconazole is effective in prophylaxis against invasive fun-
gal infections in selected patient populations, as well as for 
the treatment of some fungi, especially Aspergillus and some 
Zygomycetes. Posaconazole has been shown to be more effec-
tive than fluconazole or itraconazole for prevention of invasive 
fungal infections in patients with neutropenia from chemother-
apy, leukemia, or myelodysplastic syndrome. In the treatment of 
OPC, posaconazole is at least as effective as fluconazole in HIV 
patients with OPC. Posaconazole is effective in fluconazole/
itraconazole-resistant OPC and in the treatment of non-OPC 
fluconazole-resistant Candida species infections. Side effects 
of posaconazole are similar to fluconazole in most studies, but 
administration and absorption remain a major concern. Further 
clinical studies of posaconazole are warranted to extend the 
range of approved treatment of posaconazole. However, for 
the vast majority of OPC cases fluconazole remains the drug 
of choice due to its efficacy and lower cost.
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